NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND

A UK biotech takes aim at Parkinson’s, ALS by drugging mitochondria

The venture arms of Merck KGaA and Novartis are among the investors involved in raising $67 million for NRG Therapeutics, which aims to bring its first medicine into clinical testing next year.

NRG raises £50m to start trials of Parkinson's, ALS drug

NRG Therapeutics' oversubscribed Series B will fund first-in-human trials of a drug targeting mitochondrial dysfunction in neurodegenerative diseases

NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND

Oversubscribed £50m Series B led by SV Health Investors’ Dementia Discovery Fund, alongside other new investors British Business Bank, M Ventures, Novartis...

NRG raises £50m to start trials of Parkinson's, ALS drug – RamaOnHealthcare

NRG Therapeutics has secured the funding it needs to take a potentially first-in-class therapy for neurodegenerative diseases from preclinical development

NRG Therapeutics closes £50m Series B round

NRG Therapeutics has closed its oversubscribed £50m Series B round, which included an £8m investment from British Business Bank. NRG Therapeutics is developing novel treatments for severe neurodegenerative conditions, including amyotrophic lateral sclerosis (ALS), motor neurone disease (MND) and Parkinson’s.  The Stevenage-based business is currently preparing to move into clinical trials following strong pre-clinical data, too. The funding roun…

NRG Therapeutics raises £50m to tackle neurodegenerative disorders

A Stevenage-based neuroscience company has raised an oversubscribed £50m Series B funding round to advance its lead drug candidate.  NRG Therapeutics, which is targeting a novel mechanism to address mitochondrial dysfunction, saw the round led by SV Health Investors’ Dementia Discovery Fund (DDF). Other investors include British Business Bank, M Ventures, Novartis Venture Fund, Criteria Bio Ventures, Omega Funds, Brandon Capital and founding inv…